Ebglyss Shows Promise in Eczema Patients Unresponsive to Dupixent
Key Insights
Eli Lilly's Ebglyss (lebrikizumab) demonstrated significant improvements in skin clearance and itch reduction in patients with moderate-to-severe atopic dermatitis (search).
In a Phase 3b study, 57% of patients achieved a 75% improvement in EASI score at 16 weeks with Ebglyss after prior Dupixent treatment.
Ebglyss also improved hand and face dermatitis, with 52% of patients showing clear or almost clear facial skin at Week 24.
Eli Lilly's Ebglyss (lebrikizumab) has shown promising results in treating patients with moderate-to-severe atopic dermatitis (search) (eczema (search)) who had previously been treated with Sanofi/Regeneron's Dupixent (dupilumab). New data from the Phase 3b ADapt study, presented at the Fall Clinical Dermatology Conference, reveal that Ebglyss significantly improved skin condition and reduced itch in this patient population.
The ADapt study evaluated the efficacy of Ebglyss in patients who had an inadequate response to or discontinued dupilumab. The primary endpoint was achieving at least a 75% improvement in the Eczema (search) Area and Severity Index (EASI-75) score at 16 weeks. Secondary endpoints included an Investigator Global Assessment (IGA) score of clear (0) or almost clear (1) skin with at least a two-point reduction from baseline, and at least a four-point improvement in Pruritus NRS from baseline.
Key Findings from the ADapt Study
At Week 16, 57% of patients treated with Ebglyss achieved EASI-75, and this increased to 60% at Week 24. Furthermore, 46% of patients who were inadequate responders to dupilumab achieved EASI-75 response with Ebglyss at Week 16.
Significant itch relief was also observed, with 53% and 62% of ADapt patients who discontinued dupilumab and began Ebglyss treatment experiencing at least a four-point improvement in Pruritus NRS from baseline at Week 16 and Week 24, respectively.
Improvements in Difficult-to-Treat Areas
Ebglyss demonstrated efficacy in improving dermatitis in difficult-to-treat areas such as the face and hands. By Week 24, 52% of patients treated with Ebglyss showed clear or almost clear facial dermatitis. Among patients with moderate-to-severe hand dermatitis at baseline, the modified total lesion-symptom score, which measures the extent and severity of hand dermatitis, decreased by 75% at Week 24.
Safety Profile
The study also highlighted a favorable safety profile for Ebglyss, with less than 6% of patients experiencing an adverse event that led to treatment discontinuation.
Regulatory Status and Market Availability
The FDA approved Ebglyss in the previous month for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (search) (eczema (search)) that is not well controlled despite treatment with topical prescription therapies. Ebglyss is a targeted IL-13 (search) inhibitor.
Ebglyss was also approved in the European Union in 2023 and Japan in January 2024, with additional markets expected later this year.